Innovating the advanced wound care market
Healing chronic wounds effectively
The most efficacious, clinically proven advanced chronic wound care product line in the world.
Sterile wound cream
The first commercially available medical device, Accelerex, is for the treatment of a wide variety of chronic and acute wounds. Accelerex is a custom-designed, FDA and CE approved unit-dose, sterile wound dressing impregnated with an ointment containing QBx.
Chronic wounds are generally defined as wounds that have not healed after thirty days of consistent clinical treatment, and include diabetic ulcers, burns, pressure ulcers (bedsores), and venous stasis ulcers. The Company’s broadly-enabling technology was discovered from oak bark extract and referred to as QBx™.
Sterile impregnated wound dressing
For use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions. FDA-cleared, prescription-only combination device that blends the benefits of a wound dressing with two drug components. Provides three modes of action to help treat acute and chronic wounds:
- Protective dressing
- Moisturizing ointment
- Two drug components: rubidium chloride and potassium chloride
Liquid bandage & skin protectorant
Xcellderma™ products are sterile wound dressings and are effective for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds. During the last several years, a scientific and medical consensus has emerged that elevated protease levels impede wound healing. QBx™ the active ingredient down regulates the production of certain proteases and matrix metalloproteases, or MMPs, which are protein enzymes that are proven to impede the healing of a majority of chronic wounds. Approximately 80% of chronic wounds display elevated levels of proteases (including MMPs).
Liquid bandage & skin protectorant
Xcellderma™ products are sterile wound dressings and are effective for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds. During the last several years, a scientific and medical consensus has emerged that elevated protease levels impede wound healing. QBx™ the active ingredient down regulates the production of certain proteases and matrix metalloproteases, or MMPs, which are protein enzymes that are proven to impede the healing of a majority of chronic wounds. Approximately 80% of chronic wounds display elevated levels of proteases (including MMPs).
Sterile wound cream
The first commercially available medical device, Accelerex, is for the treatment of a wide variety of chronic and acute wounds. Accelerex is a custom-designed, FDA and CE approved unit-dose, sterile wound dressing impregnated with an ointment containing QBx.
Chronic wounds are generally defined as wounds that have not healed after thirty days of consistent clinical treatment, and include diabetic ulcers, burns, pressure ulcers (bedsores), and venous stasis ulcers. The Company’s broadly-enabling technology was discovered from oak bark extract and referred to as QBx™.
Sterile impregnated wound dressing
For use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions. FDA-cleared, prescription-only combination device that blends the benefits of a wound dressing with two drug components. Provides three modes of action to help treat acute and chronic wounds:
- Protective dressing
- Moisturizing ointment
- Two drug components: rubidium chloride and potassium chloride
What makes us different
Our mission at Regenerex Pharma, Inc. is to heal wounds effectively with our proprietary innovative formulas in the shortest period of time to minimize the chances of future complications. The products have shown to be very effective in healing chronic wounds in multiple clinical evaluations with 95% of wounds demonstrating 100% closure within 90 days. All of our products feature our proprietary QBx™ ingredients which contribute to setting up a suitable environment to allow wounds to close.
Currently, there are no products available on the market that are successful in healing chronic, non-healing wounds through the down regulation of proteases. Other modern wound dressings such as hydrocolloids and collagens absorb wound fluids, but these dressings do not impact the cellular environment with simple gauze and gauze-like dressings to cover and protect the wound.
85,000
Approximate number of adults with diabetes who-undergo amputation due to non-healing wounds annually
Annually, about 85,000 adults with diabetes undergo a leg or foot amputation due to a non-healing wound, the majority of which started with an ulcer. Our products can heal these ulcers early and in the shortest period of time thereby reducing the risk of amputation. Our research and development in QBx™ helps patients heal faster than basic generalized wound care.
America’s current chronic wound care crisis
In the United States, there are millions of people who are living with chronic wounds. According to a 2017 report published by the Centers for Disease Control and Prevention (CDC), more than 100 million people in the U.S. were suffering from diabetes or pre-diabetic conditions.These incidences of chronic wounds are mainly among the 30 million plus Americans fully diagnosed with diabetes. Our specialized Wound care products are increasingly effective to prevent surgical site infections and complications.
Advanced healing technology
Consider this:
- Approximately 80% of chronic wounds display elevated levels of MMPs (matrix metalloproteases)
- Elevated MMP levels of 2, 3 and 9 are indicative of chronic, non-responsive, slow-healing wounds
- Our active ingredient QBx™ is a synthetic composition of cations derived from a botanical material found in the ash of red oak bark which has been shown to therapeutically down regulate certain MMPs
- Regenerex’s QBx™ technology contributes to setting up a suitable environment to allow wounds to close. Other than the products marketed by us, there are no products currently available on the market that are successful in healing chronic, non-healing wounds through the down regulation of proteases.
Accelerated healing
Chronic wounds detract from your quality of life and prevent you from doing things you enjoy. Regenerex’s products provide advanced wound care that can stimulate healing effectively and in shorter period of time compared to traditional methods. Our QBx™ technology contributes to setting up a suitable environment to allow wounds to close. We are proud to serve the needs of our population to successfully heal chronic, non-healing wounds through our products that provide down regulation of proteases.
Why choose advanced wound care from Regenerex Pharma
We provide the most technologically advanced clinically proven products on the market today that heal wounds quicker, conveniently and cost effectively.
Experience and Expertise
Regenerex leads the industry in advanced wound care expertise and real world experience to provide chronic wound care sufferers with a proven solution.
Research and Innovation
Regenerex research and innovation initiatives over the past 30 years include the most scientifically and clinically advanced chronic wound specific solutions in the world. Our products set the standard for advanced wound care.
Reliability
Regnerex develops, manufactures and sources its ingredients right here in the USA under FDA guidelines.
